Our Independence Day honors how brilliant minds, when granted freedom and resources, can bring bold ideas to life. Nowhere is that promise more visible than in the fight against cancer. The United States invests more in oncology research than any other country, and the return on that investment is measured in lives saved around the globe. Pioneers on American soil introduced combination chemotherapy in the 1960s, proved the value of targeted estrogen therapy with tamoxifen in the 70s, decoded the first cancer genomes early in the new millennium, and brought CAR T-cell therapy from concept to clinic within a single decade. Each discovery grew from faith in inquiry and from institutions that reward persistence and collaboration.
The National Cancer Institute supports thousands of investigators in every state, while the Cancer Moonshot unites universities, technology firms, community hospitals, and patient advocates behind the goal of halving the national cancer death rate within 25 years. Philanthropic foundations, venture capital, and federal grants work together, creating an ecosystem where a promising idea can travel from bench to bedside. Success appears not only in breakthrough medicines but also in diagnostics that reveal disease earlier and in tools that respect the patient experience from the first appointment forward.
Koning contributes to this ecosystem through our Koning Vera device, the only dedicated breast computed-tomography platform cleared by the FDA for diagnostic use. Conceived, engineered, and manufactured in Rochester, New York, Vera reflects an American willingness to challenge the status quo. Standard mammography uses compression and two-dimensional imaging. The process can be painful, and the limited perspective may hide critical details, especially in dense tissue. Vera replaces compression with a gentle tabletop rotation that captures true 3D views at isotropic resolution below one hundred microns. A single scan takes only a few seconds, giving radiologists exquisite detail while offering patients an experience that is calm, quick, and dignified.
Survival statistics still vary by geography, income, and race, and fear of pain remains a universal barrier to regular screening. By removing discomfort and anxiety, the Koning Vera makes early detection more attainable for everyone, including people who have postponed imaging in the past. When patients know that a scan will be brief and gentle, they are more likely to keep annual appointments, and that single choice can change the course of a life. The same national curiosity that mapped the human genome now drives us to design technology that honors every patient’s comfort without sacrificing scientific rigor.
The Fourth of July invites us to recognize the vast community that moves cancer care forward. Researchers who challenge accepted theories, engineers who refine imaging platforms, physicians who translate data into personal treatment plans, and patients who volunteer for clinical trials all share a belief that tomorrow can be better than today. That belief animated the founders in 1776, and it echoes in every modern experiment that begins with ”What if”.
At Koning we ask that question every day. What if breast imaging could be clearer and gentler at the same time? What if early detection was something patients sought rather than feared? The Koning Vera proves that these possibilities are within reach, and that American innovation continues to break new ground.
As fireworks brighten the sky this Independence Day, we salute the spirit of discovery and honor the patients whose courage inspires every algorithm, every prototype, and every clinical study. Freedom is not only a political philosophy, it is also the freedom to seek care without pain, to receive answers without delay, and to envision a future defined by health rather than illness.
Happy 4th of July from Koning! We remain committed to building technology that keeps the promise of independence alive.